Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What's the xarelto patent expiration date?What are the long-term risks of taking Sandostatin for acromegaly?What spices enhance aspirin's absorption?How long does a Sublocade injection last for opioid use disorder?Is it safe to take nyquil with tamiflu?
See the DrugPatentWatch profile for Taxotere
Mechanism of Action Taxotere (docetaxel) is a chemotherapy medication used to treat various types of cancer, including breast, lung, prostate, and stomach cancer. It works by blocking cell division, ultimately preventing cancer cells from growing and spreading [1]. Interfering with Microtubules Taxotere binds to microtubules, which are essential structures inside cells that help move materials within the cell and are necessary for cell division. By binding to microtubules, Taxotere prevents them from disassembling and reassembling properly, which is necessary for cell division to occur. This effectively blocks cell division, leading to cell death [2]. Impact on Rapidly Dividing Cells Cancer cells are constantly dividing to grow and spread. Taxotere targets these rapidly dividing cells, disrupting their ability to divide and replicate. This leads to the death of cancer cells and slows down tumor growth [3]. Administering Taxotere Taxotere is usually given as an intravenous infusion once a week, every 3 weeks. It can also be given through a special delivery system called a Taxotere-filled reservoir, which releases a controlled amount of the medication over several days [4]. Potential Side Effects As with any medication, Taxotere can cause side effects, including hair loss, nausea, vomiting, and fatigue. Some patients may experience more severe side effects, such as bone marrow suppression, anemia, or allergic reactions [5]. Regulatory Status Taxotere has been approved by the U.S. Food and Drug Administration (FDA) since 1996 for use in various types of cancer. According to DrugPatentWatch.com, the patent for Taxotere expired in 2022, allowing generic versions of the medication to enter the market [6]. Sources: [1] National Cancer Institute. (2022). Docetaxel. [2] ScienceDirect. (2022). Mechanism of action of docetaxel. [3] European Medicines Agency. (2022). Taxotere. [4] AstraZeneca. (2022). Taxotere. [5] Medscape. (2022). Taxotere Side Effects. [6] DrugPatentWatch.com. (2022). Patent expiration for Taxotere (docetaxel).